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Venous thromboembolic disease (VTD) is a public health problem. We recently reported
that endothelial colony-forming cells (ECFCs) derived from endothelial cells (EC) (ECFC-
ECs) from patients with VTD have a dysfunctional state. For this study, we proposed that a
dysfunctional status of these cells generates a reduction of its proliferative ability, which is
also associated with senescence and reactive oxygen species (ROS).
Methods and results
Human mononuclear cells (MNCs) were obtained from peripheral blood from 40 healthy
human volunteers (controls) and 50 patients with VTD matched by age (20−50 years) and
sex to obtain ECFCs. We assayed their proliferative ability with plasma of patients and con-
trols and supernatants of cultures from ECFC-ECs, senescence-associated β-galactosi-
dase (SA-β-gal), ROS, and expression of ephrin-B2/Eph-B4 receptor. Compared with cells
from controls, cells from VTD patients showed an 8-fold increase of ECFCs that emerged 1
week earlier, reduced proliferation at long term (39%) and, in passages 4 and 10, a highly
senescent rate (30±1.05% vs. 91.3±15.07%, respectively) with an increase of ROS and
impaired expression of ephrin-B2/Eph-4 genes. Proliferation potential of cells from VTD
patients was reduced in endothelial medium [1.4±0.22 doubling population (DP)], control
plasma (1.18±0.31 DP), or plasma from VTD patients (1.65±0.27 DP).
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Conclusions
As compared with controls, ECFC-ECs from individuals with VTD have higher oxidative
stress, proliferation stress, cellular senescence, and low proliferative potential. These find-
ings suggest that patients with a history of VTD are ECFC-ECs dysfunctional that could be
associated to permanent risk for new thrombotic events.
Introduction
The World Health Organization (WHO) reported that thrombosis is the first cause of death
and, specifically, contemplates that venous thromboembolic disease (VTD) must be consid-
ered a public health problem [1]. VTD is a consequence of several risk factors including family
history, genetics, and environment. Searching for new risk factors for VTD may help to better
explain the pathophysiology of this disease. We previously hypothesized that it was likely that
some unknown factors may reduce the physiological process of vascular regeneration by endo-
thelial progenitor cells (EPCs) [2], in particular endothelial-colony forming cells (ECFCs).
EPCs have a robust proliferative potential identified in adult humans and peripheral blood and
have the ability of vessel formation in vivo [3]. There is evidence that they are present in the
circulation of patients with acute myocardial infarction [4] and splanchnic vein thrombosis
[5]. These data suggest the need for endothelial precursors in order to repair a dysfunctional
vessel wall [6]. Moreover, some proteins such as the EphrinB2-Eph4 complex are required
either for revascularization or to begin the cellular responses to initiate regeneration and revas-
cularization of arterial or venous vessels [7]. Some factors may change the normal physiology
of EPCs, resulting in different pathological entities. Studies show that high levels of reactive
oxygen species (ROS) are involved in chronic human diseases such as obesity, type 2 diabetes,
atherosclerosis, and cardiovascular diseases and that they may provoke endothelial dysfunc-
tion [8]. We recently reported morphological abnormalities of the mitochondria of ECFC-ECs
from VTD patients [9], suggesting mitochondrial dysfunction [10], a mechanism that may
link ROS, endothelial dysfunction in ECFC-ECs, increased production of inflammatory cyto-
kines with apoptosis, senescence, and other vascular abnormalities in patients with VTD [11–
13]. These events may all induce a reduced cell proliferation. In this study, we examine the
effects of several types of cell supernatants and ROS on senescence, apoptosis, and cellular pro-
liferation in ECFC-ECs from VTD patients.
Materials and methods
Peripheral blood samples from controls and patients with VTD
One hundred ml of peripheral blood was collected in tubes containing 1,000 IU of a sodium
heparin solution (Tecnofarma, Me´xico) from 40 healthy human volunteers (controls) and 50
VTD patients matched by age (20−50 years) and gender. Fifteen ml of peripheral blood was
collected separately and then centrifuged at 1,000 g for 15 min at room temperature to obtain
control and patient plasma. Plasma aliquots were prepared and stored at -70˚C for further
studies.
General characteristics of VTD patients and controls are shown in Table 1. All patients had a
history of recurrent unprovoked VTD (>3 episodes) and were under anticoagulation therapy
with vitamin K antagonists (86% of the patients) or with rivaroxaban (14% of the patients). Only
36% of the patients had positive results to be considered as carriers of known thrombophilia. In
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order to participate in the study, a negative D-dimer test before entering the study was required.
The last thrombotic episode must have been at least 6 months before study initiation. Patients
were excluded if they had cancer, were pregnant, had any diseases affecting the immune system,
or any known infectious disease.
Obtaining mononuclear cells (MNCs)
The method was performed as previously described [9]. Blood (100 ml) was diluted 1:1 with
phosphate-buffered saline (PBS) (Invitrogen, Grand Island, NY, USA) and overlaid onto an
equivalent volume of Ficoll-paqueTM Plus (1.077±0.001 g/ml) (GE Healthcare Bio-Sciences
AB, Sweden). Cells were centrifuged at 740 g for 30 min at room temperature. MNCs were iso-
lated and washed twice with endothelial basal medium-2 (EBM-2) (Cambrex, Walkersville,
MD, USA) supplemented with 3% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA), 10
ng/ml penicillin/streptomycin (Gibco, Grand Island, NY, USA), and 0.25 μg/ml amphotericin
B (Gibco) (complete EGM-2 medium). The number of viable nucleated cells was determined
in a Neubauer chamber (Marienfeld, Germany) using Turk solution as a diluent (Hycel,
Me´xico) and trypan blue (Hycel), respectively.
Culture of ECFCs
Cells were seeded onto six-well tissue culture plates (30 x106 cells/well; Corning, NY, USA)
pre-coated with type I rat tail collagen (BD Biosciences, Bedford, MA, USA) and incubated at
37˚C with 5% CO2 in a humidity-saturated environment. After 24 h of culture, no adherent
cells or debris were aspirated and complete EGM-2 medium was added to each well. Medium
was changed daily until colonies of ECs (ECCs) appeared. ECCs were counted by visual
inspection using an inverted microscope (Olympus CKX41, Tokyo, Japan) under 40x magnifi-
cation. ECCs were released with TrypLE Express (Invitrogen) from tissue culture plates, sus-
pended in 2 ml of complete EGM-2 media, and plated onto 25-cm2 tissue culture flasks
(Corning) coated with type 1 rat tail collagen for further passage.
Table 1. General characteristics of controls and patients with VTD.
Controls (n = 40) Patients with VTD (n = 50) P*
Male (n = 23) Female (n = 27) All (n = 50)
Age (years) (mean, range) 44 (24–52) 41 (28–52) 43 (22–54) 43 (22–54) NS
Male/female (ratio) 18/22 (0.82) 9:12 (0.75) NS
Family history of VTD (n, %) 0 17 (73.9) 19 (70.4) 36 (72.0)
Age at first VTD
Episode (mean, range)
22 (16–41) 20 (16–49) 23 (16–49) NS
Number of VTD events
(mean, range)
89 (3, 3–7) 96 (3, 3–8) 185 (3, 3–8) NS
Type of VTD events
DVT LL 38 (42.7) 43 (44.8) 81 (43.8) NS
DVT RL 25 (28.1) 29 (30.2) 56 (27.6) NS
Bilateral DVT 15 (16.8) 11 (11.5) 26 (14.0) <0.05
PE 7 (7.9) 9 (9.4) 16 (8.6) NS
DVT + PE 8 (8.9) 12 (12.5) 20 (10.8) <0.05
Other 4 (4.5) 4 (4.2) 8 (4.3) NS
VTD: venous thromboembolic disease; DVT LL: deep venous thrombosis of the left leg; DVT RL: deep venous thrombosis of the right leg; PE: pulmonary
embolism; *: male vs. female; NS: not significant.
https://doi.org/10.1371/journal.pone.0183827.t001
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Culture of human umbilical vein endothelial cells (HUVECs)
The method was performed as previously described [9]. We obtained ten umbilical cords
from products at term. HUVECs were isolated by enzymatic activity using Liberase Re-
search Grade (Roche Diagnostics, GmbH, Mannheim, Germany). Cells obtained were first
washed with PBS (Invitrogen). The pellets were re-suspended in supplemented EGM-2
medium (Lonza) and supplemented with 10% FBS (Hyclone) and antibiotics. Pellets were
then seeded in 10 ml Petri dishes (Corning). Cells in passage 4 were used as a normal posi-
tive control for the experiments.
Semiquantitative RT-PCR analysis for Ephrin-B2 and Eph-B4
Reverse transcription polymerase chain reaction (RT-PCR) was used to analyze the expression
of the Ephrin-B2 and Eph-B4 genes in ECFC-ECs in patients with VTD and controls. Total
ribonucleic acid (RNA) from ECs (1 x106) in passage 4 was isolated with a Trizol purification
system (Invitrogen, Carlsbad, CA USA) according to the supplier’s instructions. The concen-
tration and purity of RNA were determined by spectrophotometry (Quawell-Q3000) and its
integrity was determined in a 2% agarose gel (Roche, Indianapolis, IN, USA). Complementary
deoxyribonucleic acid (cDNA) was synthesized using reverse transcriptase (M-MLV) (Invitro-
gen) with 1000 ng of total RNA.
Primers used for amplification of Ephrin-B2 and Eph-B4 genes (IDT, Cambridge, MA,
USA) were as follows: Ephrin-B2 sense 5'-CTC TGT AAC GCC AGA CCA GA-3', anti-sense
5'-ATAGCT GTC GAC CTT CCC CT-3' and Eph-B4 sense 5'-CCCAGG AGA CAG GGA GCT
G-3', anti-sense 5'-GCC CAC CTG GAG GAT GAC TGT G-3'. The constitutive gene ribo-
somal protein S18 (PRS18) was used as control: sense 5'-AATCCA AAG TAC CAG ATC CGC
CCA-3', anti-sense 5'-TTT CTT GGA GGT CAC CCA-3'. PCR conditions were as follows:
one cycle at 95˚C for 5 min, then 35 cycles of denaturation at 95˚C for 30 sec, aligning at 60˚C
(PRS18), 58˚C (Ephrin-B2), and 63˚C (Eph-B4) for 60 sec, and extension at 72˚C for 60 sec fol-
lowed by a final extension at 72˚C for 10 min. Eight μl of each PCR product was loaded with
SYBR Gold (Invitrogen) in a 2% agarose gel.
Densitometry analysis was performed using an image analyzer (BioRad). As positive con-
trol for gene expression of Eph-B4 and Ephrin-B2, primary cultures of HUVECs and pulmo-
nary artery endothelial cells (PAEC) of normal humans (ATCC-used PCS-100-022) were used.
In both cases, cells used were at passage 4.
Confocal microscopy analysis
ECFC-ECs from VTD patients and controls as well as HUVECs at passage 4, were grown with
type I rat tail collagen-coverslips, in 6-well plates at 80% of confluence. Cells were rinsed twice
in PBS, fixed in 4% paraformaldehyde in complete medium for 5 min, then fixed in 4% para-
formaldehyde in PBS, and permeabilized in 0.1% Tween 20 (Biorad) for 1 h. After washing
three times with PBS, coverslips were incubated at 4˚C overnight with a rabbit polyclonal anti-
Ephrin2 and anti-Eph-4 IgG antibodies (Santa Cruz Biotechnology, USA), and with a rabbit
monoclonal anti-gamma H2A.X (phospho S140) antibody [γH2AX] (Abcam, Eugene USA).
After washing with PBS, cells were stained with 0.4% DAPI and incubated with a goat anti-rab-
bit Alexa Fluor 488 antibody (ThermoFisher Scientific, IL, USA), at room temperature during
40 min. Then, cells were washed with PBS and mounted in an aqueous media VECTASHIELD
(Vector Laboratories, Inc. Burlingame, CA.). Cell morphology and intracellular localization of
proteins were analyzed by a confocal microscope (Nikon Ti Eclipse, USA).
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Growth kinetics and estimate of replicative capacity of ECFC-ECs
At passage 2, 1 x104 ECFC-ECs were plated in six-well plates with 2 ml EGM-2. Subsequently,
when 80% cell confluence was observed, cells were harvested with TrypLE Express and coun-
ted using trypan blue. At each subsequent passage, cells were counted for calculation of a
growth kinetic curve, population-doubling times (PDTs), and cumulative population-doubling
levels (CPDLs). The number of PDs occurring between passages was calculated according to
the following equation:
PD ¼ ðLn ðnumber of cells counted=number of cells at the beginning of the assayÞ=Ln2Þ:
The sum of all previous PDs determined the CPDL at each passage. PDT was obtained by
means of the time interval between cell seeding and cell harvest divided by the number of PDs
for each passage [14].
FACS analysis
Measurement of intracellular H2O2 levels in 5 x10
4 ECFC-ECs in suspension at passage 4 was
performed after loading with 20,70-dichlorodihydrofluorescein diacetate (DCF-DA, 20 μM;
MitoSciences, Cambridge, MA, USA) for 30 min at 37˚C in the dark, washed with PBS, and
detached with TrypLE Express. After centrifugation, cell pellets were suspended in 200 μl PBS.
Formation of ROS was detected by the signal obtained from the fluorescent reaction products
2’,7’-dichlorofluorescin (DCF) and ethidium. Cells were washed and analyzed by means of
fluorescence-activated cell sorting (FACS) (FACS Calibur, Becton Dickinson, USA). Results
were analyzed using the FlowJo Software v.7.6.5 (Ashland, OR, USA). The absolute values of
mean fluorescence intensity (MFI) were expressed as percentages and the result obtained from
controls was considered as the 100% reference value. For determination of apoptosis, ECF-
C-EC in passage 4 were detached with TrypLE Express for 5 min at 37˚C, washed in PBS, and
suspended in binding buffer (BD Biosciences). After centrifugation, cell pellet was suspended
in 50 μl binding buffer and incubated for 15 min at room temperature with 2 μl annexin–fluo-
rescein isothiocyanate (FITC; BD Biosciences) and 2 μl propidium iodide (PI; BD Biosciences).
Binding buffer (300 μl) was added and cells were washed twice and analyzed by means of
FACS. We analyzed the results using FlowJo Software v.7.6.5.
To evaluate the expression of γH2AX in ECFC-ECs from controls and VTD patients at pas-
sage 4, cells were grown with type I rat tail collagen in 6-well plates at 80% of confluence. Cells
were rinsed twice in PBS, fixed in 4% paraformaldehyde in PBS for 20 min, and permeabilized
with 0.1% Triton 100 X (Sigma Aldrich USA), in PBS for 20 min at 4˚C. Then, cells were
blocked in a 1% BSA solution in PBS and incubated with a murine anti-human anti-H2AX
(pS139) PE-conjugated antibody (BD Biosciences). Labeled cells were analyzed in a FACS-
Verse (BD Biosciences), and the data obtained were evaluated with a Flowjo software (Version
10.3).
Senescence-associated β-galactosidase activity assay
Senescence-associated β-galactosidase (SA-β-gal) activity was measured as described previ-
ously. Briefly, adherent EPC at passages 4 and 10 were washed in PBS, fixed for 60 min at
room temperature in 2% paraformaldehyde, washed and incubated for 24 h at 37˚C without
CO2 and with a fresh SA-β-gal stain solution: 1 mg/ml 5-bromo-4-chloro-3-indyl-β-D-galacto-
pylanoside (X-gal; Promega, Madison, WI, USA), 5 mmol/l potassium ferrocyanide, and 2
mmol/l MgCl2. After two additional washes with PBS, stained cells (blue) were observed with
phase contrast microscopy. Cell counting was done in 100 different fields.
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Proliferation of ECFC-ECs
We prepared a mixture of plasmas from four controls and four patients with VTD (two males
and two females). Conditioned mediums (supernatants) from ECFC-ECs of four controls and
four VTD patients were collected at passage 4 after 24 h of culture (80% of confluence). ECF-
C-ECs (2 x103 cell/well) from patients and controls at passage 4 were plated in triplicate in
24-well plates under three different conditions: a) EGM-2 medium supplemented with 10%
FBS; b) EGM-2 medium supplemented with 10% plasma from patients with VTD; and c)
EGM-2 medium supplemented with 10% of control plasma. Treatments with the supernatants
were done as follows: a) EGM-2 medium supplemented with 10% FBS; b) EBM-2 medium
conditioned 24 h with ECFC-ECs from patients with VTD and supplemented with 10% FBS;
and c) EBM-2 supernatants 24 h with EPC from patients with VTD and supplemented with
10% FBS. The fold-increase (FI) population was determined by dividing the number of living
cells on day 7 by the living cells at day zero. Medium changes were performed every 24 h for 7
days of culture and cells were harvested with TrypLE Express. Live cells were counted and
then evaluated with trypan blue.
Statistical analysis
Results are expressed as mean ± standard deviation. T-test and One-way analysis of variance
test were used to analyze the results; P0.05 was considered statistically significant. Data were
analyzed with SigmaStat statistical software (v.3.5, Sigma Stat, San Jose, CA, USA).
Ethical considerations
The study protocol was approved by the National Ethics Committee of the Instituto Mexicano
del Seguro Social (authorization number IMSS-R-2014-785-030 and IMSS-R-2015-785-091).
All participants were informed about study procedures and informed, written consent was
obtained from each individual before blood samples were obtained. This study fulfilled the
principles of the Declaration of Helsinki. Human umbilical cord blood was always obtained
according to institutional guidelines.
Results
Increased number of ECFCs from VTD patients
ECCs isolated from the MNC fraction of blood samples from 40 controls (Fig 1A) and 50 VTD
patients (Fig 1B) had similar morphological characteristics and the typical cobblestone mor-
phology. In addition, number of ECCs from VTD patients in culture per 100 x106 MNCs was
higher than in controls (6.8±3.3 vs. 1.9±0.8, P0.001) (Fig 2). These results suggest that ECCs
from VTD patients may have abnormal cell proliferation and angiogenic potential that may
affect endothelial remodeling.
Impaired expression of Eph-B4/ephrinB2 in ECFC-ECs from patients
with VTD
During embryonic development, regulation of the vascular network generation depends on
the receptor EphB4 and its ligand ephrin-B2, both markers for venous and arterial beds,
respectively. However, they remain important during adult life for tissue regeneration as well
as for the pathophysiology of some diseases. We hypothesized that in ECFC-ECs from patients
with VTD, the expression of this complex was different as compared with controls. We evalu-
ated ECFC-ECs isolated from VTD patients and controls for their expression of EphB4 and
Endothelial colony-forming cells in thrombosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0183827 September 14, 2017 6 / 19
ephrin-B2 by RT-PCR. PAECs were used as a positive control for ephrin-B2 and HUVECs
were used as a positive control for EphB4 (Fig 3A). Densitometry analysis shown that expres-
sion of specific transcripts of Eph-B4 was increased (12.5±0.6) as compared with controls (9.5
±0.5). Interestingly, ephrin-B2 was reduced in ECFC-ECs from patients with VTD (13.7±2.5)
vs. controls (28.7±1.5) P = 0.017 (Fig 3B and 3C, respectively). However, when we analyzed the
presence of the protein by immunofluorescence we detected and increase in the expression of
both, EphB4 and Ephrin-B2 as compared with their normal counterparts (Fig 3D and 3E,
respectively). These data suggest the presence of abnormal mechanisms of proliferation and
revascularization or ECFC-ECs obtained from VTD patients.
Reduced proliferation in ECFC-ECs from patients with VTD
ECFC-ECs from adult peripheral blood have good proliferation potential but limited as com-
pared with ECFC-ECs from human umbilical cord blood. To investigate the potential expan-
sion of ECFC-ECs from patients with VTD and controls, we analyzed the cell growth kinetics
Fig 1. Identification of ECFCs obtained from peripheral blood from controls and patients with VTD.
Representative photomicrograph (40X magnification) of colonies formed by ECFCs in cultures of MNCs
obtained from peripheral blood after 14 days in culture. (A) controls and (B) patients with history of VTD.
https://doi.org/10.1371/journal.pone.0183827.g001
Fig 2. Frequency of ECFCs obtained from peripheral blood of controls and patients with VTD. This
figure shows the number of ECFC colonies obtained from peripheral blood of controls and patients with VTD
per 108 MNCs seeded in culture plates. Results are expressed as mean ± standard deviation of 16
independent samples in each case. *P = 0.001.
https://doi.org/10.1371/journal.pone.0183827.g002
Endothelial colony-forming cells in thrombosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0183827 September 14, 2017 7 / 19
at different passages by generating growth curves. We found that ECFC-ECs from control at
earlier (4) and late (12) passages have superior growth kinetics and reached higher densities at
confluence than cells from patients with VTD (39% reduced proliferation rate) (Fig 4). To
evaluate and quantitate the proliferation rate of ECFC-ECs from VTD patients vs. controls, we
analyzed the profiles of population doubling times (PDT) as well as the cumulative population
doublings (CPD) at passage 11 in the culture. We observed that ECFC-EC from controls have
27.37±7.07 PDT vs. 16.81±4.85 PDT in ECFC-ECs from VTD patients (P = 0.032) (Fig 4B).
We also observed that PDT required by ECFC-ECs from controls was 3.80±0.79 days, whereas
it was 7.26±2.24 days for ECFC-ECs from patients with VTD (P = 0.017) (Fig 4C). This finding
strongly suggests that there are significant deficiencies in the proliferative response of ECF-
C-ECs from patients with VTD.
ECFC-ECs from patients with VTD exhibit high rates of ROS
In a previous study, we reported that ECFC-ECs from patients with VTD have significant
abnormalities at the mitochondrial membrane level [9] and a reduced proliferation rate, which
suggested a higher presence of ROS (specifically H2O2). We then analyzed ROS levels in ECF-
C-ECs from patients with VTD and controls with DCF-DA by means of fluorescence-activated
Fig 3. Relative expression of ephrin-B2 and Eph-B4 genes in ECFC-ECs from peripheral blood of
controls and patients with VTD. (A) mRNA expression of ephrin-B2 (639 bp), Eph-B4 (251 bp) and RPS18
(240 bp) as housekeeping gene in peripheral blood samples from controls and from patients with VTD. (B)
Densitometric analysis of ephrin-B2 and (C) Eph-B4 evaluated in positive controls (HUVECs and PAECs) in
ECFC-ECs of controls and patients with VTD. Results are expressed as mean ± standard deviation of three
independent experiments in passage 4. *P = 0.017, **P = 0.01. Expression of the proteins Ephrin-B2 (D) and
Eph-B4 (E), was evaluated by confocal inmunofluorescence microscopy.
https://doi.org/10.1371/journal.pone.0183827.g003
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cell sorting (FACS). We found a significant increase of intracellular H2DCF oxidation in ECF-
C-ECs from patients with VTD (1,775.67±459.08 MFI) as compared with ECFC-ECs from
controls (807.0±205.75 MFI) (p = 0.012) (Fig 5).
Apoptosis in ECFC-ECs from patients with VTD
Once we demonstrated that ECFC-ECs from patients with VTD exhibited increased intra-
cellular ROS levels, we analyzed the degree of apoptosis by means of the expression of
annexin V-FITC. A significant increase in apoptosis in ECFC-ECs from VTD patients (5.52
±0.46%) was observed vs. expression of the controls (1.73±0.25%) (Fig 6A). These results
clearly demonstrated that ECFC-ECs from patients with VTD are more sensitive to ROS-
induced apoptosis. We also analyzed the DNA damage by means of the expression of the
associated phosphorylated histone H2AX (γH2AX) by immunofluorescence (Fig 6B), and
flow cytometry analysis (Fig 6C). Our results show an increase in the level of DNA damage
in ECFC-ECs from patients with VTD as compared with controls.
Senescence in ECFC-ECs from patients with VTD
Because an impaired expression of Ephrin-B2 and eph-4 genes as well as reduced proliferative
capacity and ROS in ECFC-ECs from VTD patients were found as compared with controls, we
Fig 4. Proliferative potential of ECFC-ECs from peripheral blood of controls and patients with VTD.
This figure shows the results from ECFC-ECs obtained from VTD patients and controls regarding the
following: (A) Proliferation of ECFC-ECs. Each point on the graph indicates the accumulated cell number
along different reseedings. (B) Cumulative population doubling (CPD) levels. (C) Population doubling times
(PDT). Results are expressed as mean ± standard deviation of five independent experiments. *P = 0.032 for
CPDs and **P = 0.017 for PDTs.
https://doi.org/10.1371/journal.pone.0183827.g004
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attempted to determine whether these abnormalities were likely associated with senescence
because morphological changes and appearance of enlarged flattened cells in ECFC-ECs from
VTD patients were observed. Therefore, we investigated the rate of senescence using SA-B-gal
staining. ECFC-ECs from patients with VTD were highly senescent (30±1.05%) at passage 4 as
compared with controls (10±0.98%) (Fig 7A and 7B) (p = 0.001). Interestingly, at passage 10,
the senescence increased to 52.09±11.44% and 91.3±15.07% in ECFC-ECs from controls and
patients with VTD, respectively. These results strongly suggest that, in ECFC-ECs from
patients with VTD, addition of the above-mentioned abnormalities may reduce their prolifer-
ative capacity and may induce increased senescence.
Effect of plasma and supernatants on the proliferation of ECFC-ECs in
patients with VTD
In order to investigate the likely role of the microvascular environment on the proliferative
potential of ECFC-ECs obtained from patients with VTD and controls, we substituted the
bovine fetal serum used in the medium (control medium) with previously collected plasma
from patients with VTD and controls. Fig 8A shows that the proliferative potential of ECF-
C-ECs obtained from patients with VTD was lower when incubated with control medium [1.4
±0.22 doubling population (DP)], plasma from control subjects (1.18±0.31 DP), or with
plasma from VTD patients (1.65±0.27 DP). In contrast, ECFC-ECs obtained from control
individuals showed a higher proliferative capacity under the same three previously described
culture conditions: control medium (2.5±0.44 DP), plasma obtained from control individuals
(3.36±0.03 DP), and plasma obtained from patients with VTD (2.080±0.25 DP). However, it
should be emphasized that when these last cells were incubated with plasma from control indi-
viduals, the proliferation rate was significantly higher as compared with the results obtained
with control medium and plasma obtained from patients with VTD.
In another series of experiments, we used control medium or supernatants of the ECF-
C-ECs cultures (incubated with conditioned medium) obtained from patients with VTD or
Fig 5. Expression of ROS in ECFC-ECs obtained from blood of controls and patients with VTD. Mean
fluorescence intensity (MFI) emitted by 2’,7’-dichlorofluorescein (DCF) in ECFC-ECs from peripheral blood
samples of controls and patients with VTD in passage 4. MFI was expressed as percentage being 100% the
value obtained by ECFC-ECs from controls. The results are expressed as mean ± standard deviation of three
independent experiments *P = 0.012.
https://doi.org/10.1371/journal.pone.0183827.g005
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control subjects. Fig 8B shows that the proliferative potential of ECFC-ECs from VTD patients
incubated with control medium (1.39±0.22 DP), supernatants of ECFC-ECs obtained from
control individuals (1.06±0.16 DP), or supernatants obtained from patients with VTD (0.65
±0.48) was significantly lower as compared with the proliferative potential of the ECFC-ECs
obtained from control individuals when incubated with control medium (2.50±0.29 DP),
supernatants of ECFC-ECs from control individuals (1.88±0.23 DP) or supernatants of ECF-
C-ECs obtained from patients with VTD (0.760±0.45 DP).
Discussion
VTD is currently considered a public health problem although its exact incidence is unknown.
It is calculated that each year 10 million people are affected by a new episode of VTD world-
wide. As a consequence, VTD is considered a major contributor to the global disease burden.
Fig 6. Apoptosis in ECFC-ECs obtained from peripheral blood of controls and patients with VTD. The
figure shows the percentage of ECFC-EC annexin V-FITC positive (A) and the presence of DNA damage
evaluated by the expression of γH2AX histone by immunofluorescence (B) as well as flow cytometry analysis
(C), in passage 4. Results are expressed as mean ± standard deviation of three independent experiments.
*P = 0.002 for annexin expression.
https://doi.org/10.1371/journal.pone.0183827.g006
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This is one of the major reasons why it is important to investigate the unknown risk factors
associated with this disease as well as to delve more deeply into its pathophysiological mecha-
nisms in order to reduce the high rates of morbidity and associated mortality in the near future
[1,15].
EPCs were described in 1997 [16] and a body of studies immediately began in order to iden-
tify their contribution to several vascular diseases such as arterial hypertension [17], athero-
thrombotic disease, cerebral ischemia [18], and diabetes [19]. It has been described that
ECFCs are sensitive to oxidative stress (a phenomenon described in acute myocardial infarc-
tion) [20] and splanchnic vein thrombosis [5]. However, in general, their contribution to the
pathogenesis of other vascular abnormalities has been poorly analyzed. Because there are no
reports describing the association of ECFC abnormalities and oxidative stress, we attempted to
gain information in patients with recurrent, chronic VTD.
Our study focused on the evaluation of the effect of oxidative stress on the potential prolif-
eration of ECFC-ECs obtained from the peripheral blood of patients with VTD. We aimed to
understand whether such a mechanism could be related to venous thrombotic events in
patients experiencing recurrent episodes in whom an endothelial dysfunction may be present,
Fig 7. Senescence in ECFC-ECs obtained from peripheral blood of controls and patients with VTD.
SA-β-gal activity analysis was used as a marker of cell senescence. (A) Representative images from controls
and patients with VTD-ECFCs at passage 4 (P4) and 10 (P10) (upper panel, magnification X100; scale bar,
200 μm). (B) Percentage of senescent cells in patients with VTD-ECFCs was determined with the number of
cells expressing SA-β-gal (blue cells) related to the total number of cells/field from patients with VTD (n = 3) or
controls (n = 3). Graph (lower panel) represents mean ± SEM of five independent samples. Experiments were
done in triplicate. *P = 0.001 (patients with VTD vs. controls at passage 4); **P = 0.023 (patients with VTD vs.
controls at passage 10).
https://doi.org/10.1371/journal.pone.0183827.g007
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despite the use of anticoagulant therapy such as vitamin K antagonists or rivaroxaban. We did
not find significant differences in terms of the size and shape of ECCs obtained from controls
and patients with VTD. Interestingly, in patients with VTD, we found an increase of circulat-
ing ECCs, suggesting a mechanism of response to chemotactic signals that could induce a
dysfunctional endothelium in order to replace ECs and to promote revascularization of the
damaged vascular network [21]. This is the case of patients with acute myocardial infarction in
whom there is an increase of EPCs that apparently favors the vascular repair process [4].
Recent evidence found an increased frequency of EPCs in the peripheral blood of patients
with coronary artery disease and perhaps may be considered an indicator of risk for suffering a
new thrombotic event [22]. It is suggested that intracellular ROS are a determining factor in
the mobilization of EPCs resembling a phenomenon occurring with hematopoietic stem cells
(HSC) and hematopoietic progenitor cells (HPC) as they are released from the bone marrow
[23]. In this regard, expression of transcripts Ephrin-B2 and Eph-B4 in EPCs plays an important
role in vascular formation during embryonic development and postnatal revascularization pro-
cesses, which coordinate venous or arterial traffic of ECs in case of vascular repair. We found
increased transcript expression of Eph-B4 and a low transcription expression for Ephrin-B2 in
ECFC-ECs from patients with VTD. Both findings were consistent with previous data demon-
strating an increased Eph-B4 transcript expression in EPCs from mouse and human. This plays
Fig 8. Effect of plasma and supernatants on the proliferative potential of ECFC-ECs obtained from
peripheral blood of controls and patients with VTD. (A) The figure shows the number of ECFC-ECs in
controls and patients with VTD at passage 4 after stimulation with plasma obtained from controls and patients
with VTD. (B) Results of the 24-h incubation of supernatants and ECFC-ECs from VTD patients and controls.
Results are expressed as mean ± standard deviation of three independent experiments, *P0.05, **P0.05.
https://doi.org/10.1371/journal.pone.0183827.g008
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an important role in the remodeling of venous endothelium [24] as well as in vein formation
during embryonic and postnatal development, respectively [25]. In this study, we found an
increased expression of Eph-B4 and Ephrin-B2 proteins in ECFC-ECs from patients with VTD
and we believe that this phenomenon could be associated with major abnormalities occurring
in these cells.
The increased frequency of circulating ECFC-ECs and the high expression of Eph-B4
observed in patients with VTD suggest they have a high proliferative capacity, which may be
useful to induce an efficient revascularization process. However, when we evaluated their pro-
liferation potential, they showed a reduced proliferation rate of 50% at 4 months of time (times
at which we eliminate the cultures). This fact shows a reduction of 15 duplications and 4 days
in order to double the cell population. Our data agree with previous reports that indicated a
low rate of EPC proliferation in patients with hypercholesterolemia, intrauterine growth
restriction, and heart disease [26,27]. In our study, we attempted to find changes in the angio-
genic function of CPEs secondary to a challenging environment capable of inducing oxidative
stress [28]. Mitochondria are involved due to having several important metabolic functions
such as calcium regulation and activation of cell death, being the most important inductors of
ROS. As a consequence, abnormal mitochondrial function may accelerate some processes like
inflammation, cell senescence, and apoptosis. Recent evidence indicates that mitochondrial
dysfunction contributes significantly to the pathogenesis of cardiovascular disease, an entity
characterized by damaged DNA [29].
We found morphological changes in mitochondria and an increased pro-inflammatory
cytokine profile (IL-6, IFN-γ, and TNF-α) in the supernatants of cultures of ECFC-ECs from
VTD patients [9]. Our results also showed increased ROS levels produced by ECCF-ECs of
VTD patients, specifically hydroxyl radicals and hydrogen peroxide, a fact that strongly sug-
gests that the low proliferative rate observed in these cells may be closely related to their dys-
functional status. This low proliferative rate may be related to the overproduction and chronic
exposure to oxidative stress either generated by the resident vessel cells or during the migra-
tion process from circulation to damaged vessel sites that require remodeling. Although the
mechanisms responsible for the dysfunction of EPCs are complex and still not fully under-
stood, we know that oxidative stress plays a key role in EPC dysfunction of some cardiovascu-
lar diseases such as hypertension, hyperlipidemia and stroke. Therefore, we believe that this
oxidative stress may be a significant contributor to the dysfunctional status observed in ECF-
C-ECs from patients with recurrent VTD [30,31].
Some studies suggest that EPCs are more resistant to oxidative stress because of their higher
expression of antioxidant enzymes that protect themselves, thus allowing a more appropriate
repair of blood vessels damaged in the hyperoxidative environment of ischemic tissues [32,33].
Some events associated with an increased oxidative stress may lead to mobilization of dysfunc-
tional EPCs [34]. This suggests the presence of abnormal proliferative mechanisms such as
cyclin D1 synthesis or activation of cyclin-dependent kinase 4 (CDK4) [35] and lower cell sur-
vival mediated through regulation of anti-apoptotic components such as BCL-2 [36]. This may
lead EPCs from patients with VTD to an accelerated apoptotic or cell senescence condition,
two mechanisms capable of reducing the ability of EPCs to properly work in the revasculariza-
tion procedures at endothelial level.
Although there is a significant difference in the percentage of cells in apoptosis between
ECFC-ECs from patients with VTD and controls, in both cases it is relatively low, considering
that apoptosis has a major role in reducing the proliferation rate of EPCs. In vitro tests have
shown that high concentrations of hydrogen peroxide are necessary to induce >10% of apo-
ptosis in EPCs [37]. Similarly, it was reported that EPCs derived from cord blood are more
resistant to cell death compared with HUVECs, suggesting that EPCs are less susceptible to
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apoptosis [14]. Interestingly, our data show increased levels of DNA damage, an event that
could be related with cellular senescence. However, it is important to underline that we also
found in cytoplasm expression of the γH2XA enzyme in ECFC-ECs from VTD patients, a fact
that may suggest that the presence of extra-nuclear DNA is the result of abnormal activation of
signal pathways related to cell death as previously described in other cell types [38]. In addi-
tion, it has been reported that the exogenous presence of histones in CFCE can inhibit prolifer-
ation and angiogenic function inducing apoptosis or pyroptosis, through the formation of
pores or use existing channels through the depolarization of the cellular membrane and the
influx of calcium [39, 40]. This leads us to assume that in CFCE-EC from patients with VTD,
the intrinsic presence of γH2XA enzyme is directly related to events of angiogenesis and active
vasculogenesis such as ischemic tissue [41]. However this interesting issue remains to be inves-
tigated, because in our previous report we identified alterations of mitochondrial membrane
in ECFC-EC from VTD patients [9].
Several conditions associated with an increased oxidative stress, e.g., hyperhomocysteine-
mia and organ ischemia, have been linked to EPC dysfunction, particularly through the induc-
tion of senescence in adults and neonates [42, 43]. In our study, senescence was related to the
activity of β-galactosidase in ECFC-ECs from patients with VTD at passage 4 as also occurs in
other in vitro studies. This fact strongly suggests that oxidative stress induces an early entry to
cellular senescence because it may occur in in EPCs from preterm neonates [42,44] as well as
from adults with coronary artery disease [45]. In our study, in patients with VTD, the observed
senescence could be induced by oxidative stress and not exclusively by telomere shortening as
occurs in replicative senescence [46].
Studies addressing cellular senescence of EPCs have not been carried out as in our study,
except in the study by Vassallo et al. who observed 85% increase in EPC senescence in culture
up to passage 10. Based on this finding we believe that ECFC-ECs from patients with VTD
have normal capabilities leading to an early senescence, perhaps through an increase of
p16INK4a inhibitor, which would induce cell arrest in the G0/G1 phases of the cell cycle
[38,47,48].
We attempted to determine if the low proliferation potential, the increase of ROS, and the
cellular senescence observed in ECFC-ECs from patients with VTD were likely caused by pro-
inflammatory cytokines present in the plasma or supernatants of cultures from ECFC-ECs as
recently demonstrated [9]. We found that ECFC-ECs from patients with VTD exhibit a low
proliferative response to angiogenic stimuli of vascular endothelial growth factor (VEGF) in
normal plasma and in the supernatants of ECFC-ECs obtained from controls. Also, prolifera-
tion of ECFC-ECs obtained from controls was significantly decreased after being incubated
with plasma or supernatants from ECFC-ECs obtained from patients with VTD. Similar
results were found by other groups describing that in plasma and supernatants of EPCs from
patients with pulmonary hypertension and heart disease, there are factors inducing an anti-
angiogenic effect that accelerate the onset of early senescence in EPCs through increased oxi-
dative stress [49–51]. These data strongly suggest that dysfunction of ECFC-ECs observed in
patients with VTD may be caused by intrinsic factors that induce the activation of one or sev-
eral senescence pathways related to oxidative stress that may affect the normal proliferative
response of progenitor cells to external stimuli and, consequently, predisposing to endothelial
dysfunction and subsequently, to new thrombotic events in patients with VTD.
This is the first study addressing the likely effects of oxidative stress on EPCs from patients
with a history of VTD after 4 months of culture. Future studies are needed to define the role of
ROS and signaling pathways on stress-induced CPE senescence before being considered as an
option to promote endothelial repair and regeneration in patients with thrombotic diseases.
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Conclusions
Our study shows that dysfunction of ECFC-ECs obtained from patients with VTD is associated
with increased oxidative stress and cellular senescence. Moreover, our results strongly suggest
that patients with a history of VTD may be at risk of new thrombotic events due to a low prolif-
erative potential of their CPEs, a fact that secondarily may be associated with a defective
response to abnormal changes in the vascular microenvironment, perhaps leading to subse-
quent thrombotic events.
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